PENZBERG, Germany--(BUSINESS WIRE)-- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Exiqon (NASDAQ OMX: EXQ) join marketing forces for Roche Applied Science´s RealTime ready assays and Exiqon`s miRCURY LNA™ ...
Small platform supporting state-of-the-art technology for fast PCR protocols introduced at American Society of Human Genetics meeting in Montreal The new LightCycler Nano instrument shares the ...
Roche has an ongoing program to develop a real-time PCR assay that detects mutations in the PI3K oncogene. The assay will run on Roche's cobas ® 4800 System. Roche intends to make the PI3K PCR assay ...
PLEASANTON, Calif., Feb. 23, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion of the COVID-19 PCR portfolio to the cobas Ⓡ 5800 System, a recently launched ...
The new LightCycler Nano instrument shares the state-of-the-art technology of the LightCycler portfolio, producing high quality data in qPCR, genotyping, and high resolution melting on a small ...
As indicated by respective links on their websites, each system will complement the cooperator ´s product portfolio. A bundle of measures like webinars and seminars and linked internet appearances are ...
Roche announced that the company has obtained a worldwide co-exclusive license for the biomarker PI3K (phosphoinositide 3-kinase) from QIAGEN to develop real-time and endpoint PCR diagnostic assays.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results